Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase NA 1Phase 1 1

Status

Terminated 2Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 2Dermatologic 2Head & Neck 1Gynecologic 1

Conditions

Melanoma 2Carcinoma, Non-Small-Cell Lung 2Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Lung Neoplasms 1Lung Diseases 1Carcinoma 1Bronchial Neoplasms 1

Interventions

pembrolizumab 524Specimen Handling 383Carboplatin 377Magnetic Resonance Spectroscopy 336Cisplatin 332Nivolumab 308Cyclophosphamide 298Radiotherapy 257Paclitaxel 255Gemcitabine 235Biopsy 235Bevacizumab 218Dexamethasone 169durvalumab 168Oxaliplatin 163Capecitabine 158Rituximab 157Fluorouracil 149venetoclax 147Docetaxel 147Etoposide 142Drug Therapy 142atezolizumab 141Doxorubicin 134Ipilimumab 129Radiosurgery 120Prednisone 120Lenalidomide 119Leucovorin 113fludarabine 109

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Toll-Like Receptor 1 × 1 year × Clear all
NCT03645928 2026-05-15

Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors

Iovance Biotherapeutics, Inc.

Phase 2 Terminated
225 enrolled
DermatologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma

NCT04614103 2026-04-15

Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

Iovance Biotherapeutics, Inc.

Phase 2 Recruiting
170 enrolled
Thoracic

Bronchial Neoplasms, Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms

NCT07406724 2026-02-12

HS-IT101 Injection Versus Chemotherapy in the Treatment of Advanced Melanoma

Qingdao Sino-Cell Biomedicine Co., Ltd.

Phase 2 Not yet recruiting
90 enrolled
Dermatologic

Melanoma

NCT03108495 2025-09-17

Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma

Iovance Biotherapeutics, Inc.

Phase 2 Terminated
210 enrolled
Gynecologic

Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡